BioWorld MedTech

Aug. 27, 2010

Deals roundup: Novartis buys majority stake in Alcon for $23.3B

Novartis (Basel, Switzerland) and Nestlé (Vevey, Switzerland) say they have completed the purchase and sale of nearly 156 million shares of Alcon (Huenenberg, Switzerland) for $28.3 billion in cash. (Medical Device Daily) Read More

TRT enlists 'soft' shock wave to help heal tissue

International report: Medtronic receives Canadian okay for RF ablation system

FDA publishes draft guidance for benign prostatic hyperplasia

Washington roundup: Atlanta's St. Joe's hospital certified for VAD implant

MDD's food for med-tech thought

Financings roundup: Cardiac Concepts grabs $27M for sleep apnea pacing device

People in the News

Agreements/contracts: Lockheed Martin, HHS support health information

Med-Tech Notes

Product Briefs

DePuy Ortho voluntarily recalls ASR hip system

MDD's Diagnostic Extra

Today's news in brief

BioWorld

BioWorld briefs for May 22, 2026.

Sangamo presents primate data for prion suppressor ST-506

BioWorld Science

Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...

TREM2 agonists detailed in Pfizer patent

BioWorld Science

Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.

Unmasking the X: EPAC2 shifts the fragile X landscape

BioWorld

Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...

Recludix presents STAT1/3 inhibitors for dermatological diseases

BioWorld Science

Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.